OnKure Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for OnKure Therapeutics, Inc. (OKUR) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021
Period EndingDec 2024Dec 2023Dec 2022Dec 2021
Operating Activities
Net Income-52.67-77.39-51.96-39.77
Depreciation & Amortization0.660.170.090.25
Stock Based Compensation4.530.200.050.00
Change in Working Capital-3.9512.641.40-2.80
Change in Accounts Payable0.001.712.650.00
Change in Other Working Capital-3.95-1.71-0.530.00
Other Operating Activities0.320.893.114.34
Net Cash from Operating Activities-51.12-63.68-47.36-37.98
Investing Activities
Capital Expenditures-0.050.220.350.20
Sales/Maturities of Investments15.9310.74-57.50-23.18
Net Cash from Investing Activities15.8710.52-57.84-23.38
Financing Activities
Debt Repayment6.000.000.000.00
Common Stock Issued58.914.670.1984.61
Other Financing Activities51.22-0.72-1.380.00
Net Cash from Financing Activities116.1360.870.47132.41
Summary
Net Change in Cash80.897.71-104.7371.05
Cash at Beginning of Period29.8819.93124.6653.61
Cash at End of Period110.7619.9319.93124.66
Free Cash Flow-51.17-63.90-47.71-38.18